CONTENTS

Issue 74 | September 2018

Has trust in big pharma plummeted?

How can big pharma restore its credibility in the eyes of patients and policymakers?

the world's most successful drug

Exploring the highs and lows of

the world’s bestselling drug, Humira

Understanding gene therapy

We examine Bluebird Bio's innovative technology and business model

A research headache

What can be done to improve the understanding of chronic migraine?

The ISPE Foundation

Why has ISPE gone down the philanthropic route with its new foundation?

Insight from Globaldata

Analysts from GlobalData break down the key trends and innovations in pharma

Master Data Management 2.0

Life sciences firms need to adapt how they approach data management

Transforming healthcare with digital tech

The industry is undergoing dramatic change as new tech brings disruption

02/23/2024 23:29:08
  • Home | Trust In Big Pharma
  • Editorial
  • NSF
  • Contents
  • Daiichi Jitsugyo
  • News
  • Freudenberg
  • The Pharma Industry Briefing
  • Fisher Clinical Services Company Insight
  • Fisher Clinical Services
  • The People vs Big Pharma: tackling the industry’s trust issues
  • Scandinavian Health Ltd. Company Insight
  • Scandinavian Health Ltd.
  • Humira: the highs and lows of the world’s most successful drug
  • Wilhelm Haselmeier GmbH & Co KG Company Insight
  • Wilhelm Haselmeier GmbH & Co. KG
  • Gene therapy: talking smart solutions with Bluebird Bio
  • Moehs Iberica Company Insight
  • Moehs Iberica SL
  • A research headache: improving the understanding of chronic migraine
  • Sensitech
  • HOF Sonderanlagenbau Company Insight
  • HOF Sonderanlagenbau
  • Philanthropy in pharma: a look inside the ISPE Foundation
  • DelSiTech
  • Novel Oral Therapies Are An Unmet Need For Ulcerative Colitis
  • Phoenix
  • FDA removes key barrier to US biosimilar development
  • Nipro PharmaPackaging
  • Pfizer price hikes: do rare cancer drugs warrant higher prices?
  • Alpex
  • Head-to-head: competing for the most effective psoriasis drug
  • Mecmesin Company Insight
  • Mecmesin
  • Takeda to seek label expansion for Ninlaro in multiple myeloma
  • Capsugel Company Insight
  • Contract Pharmaceuticals Limited Canada
  • Epilepsy: Zogenix’s ZX008 set for showdown with GW Pharma’s Epidiolex
  • Ecocool
  • Abiogen Pharma
  • Illegal online pharmacies: how endemic are they?
  • Global Freight Solutions Ltd
  • The boom in medical cannabis research is set to continue
  • AtoZ-CRO GmbH Company Insight
  • AtoZ-CRO GmbH
  • Population boom will boost acute stroke market, particularly in China
  • Pall Biotech
  • Cryo Store
  • Watch Alibaba instead of Amazon in healthcare
  • WIKA - Disaster prevention
  • AstraZeneca’s Lynparza maintains lead in PARP inhibitor race
  • G.F.
  • Erdmann Design Switzerland
  • CMV presents a serious concern in HIV+ persons
  • BEA Technologies
  • Baxter
  • bDMARD therapy: adherence in the first year is key to success
  • Pharma Support Services Ltd Company Insight
  • Pharma Support Services Ltd
  • End the struggle: pathways to HEAL the opioid crisis
  • Lauda
  • AbbVie poised to overtake Gilead as hepatitis C leader
  • ILC Dover Inc
  • ViiV results show the importance of INIs to future HIV treatment
  • Pfanstiehl
  • Novartis acquires rights to atopic dermatitis candidate MOR106
  • Niconex Medical Ltd
  • Events
  • Next issue
08/24/2018 00:00:00